News

Video

Managing Stage-III NSCLC with Actionable EGFR or ALK Mutations

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Related Content
Chronic Lymphocytic Leukemia
November 13th 2024

Piecing Together the Proper BTK Usage in CLL

D. Ross Camidge, MD, PhD; Duncan McLaren, MBBS, BSc, FRCR, FRCP, consultant clinical oncologist, Spire Edinburgh Hospitals Murrayfield and Shawfair Park, professor, Edinburgh Cancer Research Centre, The University of Edinburgh
November 13th 2024

Clinical Oncology Bridges Gaps Between Medical Oncology, Radiation Oncology, and Clinical Research: With D. Ross Camidge, MD, PhD; and Duncan McLaren, MBBS, BSc, FRCR, FRCP

LASZLO – stock.adobe.com
November 13th 2024

TAB-Follicular Lymphoma

Premal Thaker, MD, MS, David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology, director, Gynecologic Oncology Clinical Research, interim chief, Division of Gynecologic Oncology, School of Medicine, Washington University in St. Louis, Siteman Cancer Center
November 11th 2024

Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS

Pacritinib in myelofibrosis Image credit: Ifti Digital– stock.adobe.com
November 13th 2024

Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis

Fotograf – stock.adobe.com
November 13th 2024

Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS